Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

SHIRIN SHAFAZAND

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1225044738
CMS profile
654391
Location
MIAMI, FL

General Payments · PY2018–2024

$160,535.22

  • Reported across 76 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$11,151.00

11 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $11,151.00 11

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Acerta Pharma LLC $10,371.00 10
ResMed Corp $780.00 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $75.56 4
PY2019 $62.60 3
PY2020 $29,807.65 9
PY2021 $89,694.50 18
PY2022 $6,495.00 12
PY2023 $23,248.91 19
PY2024 $11,151.00 11

Payment records · PY2024 (11)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AstraZeneca Pharmaceuticals LP $900.00 01/05/2024 Consulting Fee Undisputed 01/23/2026 1104387235 CMS
AstraZeneca Pharmaceuticals LP $900.00 01/05/2024 Consulting Fee Undisputed 01/23/2026 1105645118 CMS
AstraZeneca Pharmaceuticals LP $750.00 07/03/2024 Consulting Fee Undisputed 01/23/2026 1105600727 CMS
AstraZeneca Pharmaceuticals LP $1,361.50 08/30/2024 Consulting Fee Undisputed 01/23/2026 1104238569 CMS
AstraZeneca Pharmaceuticals LP $1,361.50 08/30/2024 Consulting Fee Undisputed 01/23/2026 1104268819 CMS
AstraZeneca Pharmaceuticals LP $1,361.50 08/30/2024 Consulting Fee Undisputed 01/23/2026 1104299580 CMS
AstraZeneca Pharmaceuticals LP $1,361.50 08/30/2024 Consulting Fee Undisputed 01/23/2026 1104541892 CMS
AstraZeneca Pharmaceuticals LP $1,100.00 10/18/2024 Consulting Fee Undisputed 01/23/2026 1105607169 CMS
AstraZeneca Pharmaceuticals LP $175.00 11/07/2024 Consulting Fee Undisputed 01/23/2026 1105218431 CMS
AstraZeneca Pharmaceuticals LP $1,100.00 12/05/2024 Consulting Fee Undisputed 01/23/2026 1105223147 CMS
Resmed Corp $780.00 07/04/2024 Consulting Fee Undisputed 01/23/2026 1140204036 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.